These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 15812201

  • 1. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY.
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
    [Abstract] [Full Text] [Related]

  • 2. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB, Halperin JL.
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [Abstract] [Full Text] [Related]

  • 3. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW, SPORTIF Investigators.
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [Abstract] [Full Text] [Related]

  • 4. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators.
    Cerebrovasc Dis; 2006 Dec; 21(4):279-93. PubMed ID: 16449807
    [Abstract] [Full Text] [Related]

  • 5. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators.
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [Abstract] [Full Text] [Related]

  • 6. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ, Lip GY.
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [Abstract] [Full Text] [Related]

  • 7. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators.
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [Abstract] [Full Text] [Related]

  • 8. Trials and tribulations of non-inferiority: the ximelagatran experience.
    Kaul S, Diamond GA, Weintraub WS.
    J Am Coll Cardiol; 2005 Dec 06; 46(11):1986-95. PubMed ID: 16325029
    [Abstract] [Full Text] [Related]

  • 9. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL.
    J Am Coll Cardiol; 2005 Jan 04; 45(1):1-9. PubMed ID: 15629364
    [Abstract] [Full Text] [Related]

  • 10. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL.
    Expert Rev Cardiovasc Ther; 2004 Mar 04; 2(2):163-74. PubMed ID: 15151465
    [Abstract] [Full Text] [Related]

  • 11. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H, Selçuk MT, Maden O.
    Anadolu Kardiyol Derg; 2007 Mar 04; 7(1):54-8. PubMed ID: 17347079
    [Abstract] [Full Text] [Related]

  • 12. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S, Giansante C.
    Ital Heart J Suppl; 2004 Sep 04; 5(9):705-11. PubMed ID: 15568608
    [Abstract] [Full Text] [Related]

  • 13. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
    Kulbertus H.
    Rev Med Liege; 2003 Dec 04; 58(12):770-3. PubMed ID: 14978854
    [Abstract] [Full Text] [Related]

  • 14. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL.
    Rev Cardiovasc Med; 2004 Dec 04; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [Abstract] [Full Text] [Related]

  • 15. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
    Akins PT, Feldman HA, Zoble RG, Newman D, Spitzer SG, Diener HC, Albers GW.
    Stroke; 2007 Mar 04; 38(3):874-80. PubMed ID: 17255547
    [Abstract] [Full Text] [Related]

  • 16. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 17. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
    Ford GA, Choy AM, Deedwania P, Karalis DG, Lindholm CJ, Pluta W, Frison L, Olsson SB, SPORTIF III, V Investigators.
    Stroke; 2007 Nov 24; 38(11):2965-71. PubMed ID: 17885258
    [Abstract] [Full Text] [Related]

  • 18. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
    Olsson SB, Executive Steering Committee of the SPORTIF III Investigators.
    Lancet; 2003 Nov 22; 362(9397):1691-8. PubMed ID: 14643116
    [Abstract] [Full Text] [Related]

  • 19. Ximelagatran: a new oral anticoagulant.
    Hrebickova L, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Nov 22; 5(6):397-408. PubMed ID: 14633322
    [Abstract] [Full Text] [Related]

  • 20. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
    Reiffel JA.
    Curr Opin Cardiol; 2004 Jan 22; 19(1):58-63. PubMed ID: 14688636
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.